Atherosclerotic cardiovascular diseases in Belgium: A cost-of-illness analysis

Cardiovascular Drugs and Therapy

Volumn 22, Issue 6, 2008, Pages 487-494

  Vlayen, Joan ^a   De Backer, Guy ^b   Peers, Jan ^a   Moldenaers, Ingrid ^a   Debruyne, Hans ^a   Simoens, Steven ^c  

^a Deloitte   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Atherosclerotic cardiovascular diseases; Belgium; Cost of illness analysis; Established disease; Pre clinical disease

Indexed keywords

AMBULATORY CARE; ARTICLE; ATHEROSCLEROSIS; BELGIUM; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; COST OF ILLNESS; DIAGNOSTIC TEST; EMERGENCY CARE; EMPLOYER; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOME CARE; HOSPITALIZATION; HUMAN; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PRODUCTIVITY; SENSITIVITY ANALYSIS;

EID: 55949088183     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-008-6128-5     Document Type: Article

References (47)

1. World Health Organization. The World health report 2004-changing history. Geneva: World Health Organization; 2004.
2. Flemish Agency for Care and Health. Mortality from cardiovascular diseases. http://www.zorg-en-gezondheid.be/doodsoorzaken.aspx. Accessed 22 Apr 2008.
3. F Levi F Lucchini E Negri C La Vecchia 2002 Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world Heart 88 119 124
4. B Unal JA Critchley S Capewell 2004 Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000 Circulation 109 1101 1107
5. I Graham D Atar K Borch-Johnsen G Boysen G Burell R Cifkova 2007 European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice Eur J Cardiovasc Prev Rehabil 14 E1 40
6. Bartholomeeusen S, Buntinx F. Incidentie van hypertensie en hyperlipidemie in de huisartspraktijk (Incidence of hypertension and hyperlipidemia in general practice). Leuven: Academic Center for General Practice, Katholieke Universiteit Leuven; 2003.
7. Bartholomeeusen S, Truyers C, Buntinx F. Ziekten in de huisartspraktijk in Vlaanderen (Illnesses in general practice in Flanders). Leuven: Academic Center for General Practice, Katholieke Universiteit Leuven; 2004.
8. D De Bacquer G De Backer 2006 The prevalence of concomitant hypertension and hypercholesterolaemia in the general population Int J Cardiol 110 217 223
9. S De Henauw D De Bacquer W Fonteyne M Stam M Kornitzer G De Backer 1998 Trends in the prevalence, detection, treatment and control of arterial hypertension in the Belgian adult population J Hypertens 16 277 284
10. Debacker N, Nobels F, Scheen A, Van Casteren V, Van Crombrugge P, Vandenberghe H. Initiatief voor Kwaliteitsbevordering en Epidemiologie bij Diabetes (Initiative for Quality Enhancement and Epidemiology of Diabetes). Brussels: Wetenschappelijk Instituut Volksgezondheid; 2005.
11. Demarest S, Gisle L, Hesse E, Miermans PJ, Tafforeau J, Van der Heyden J. Gezondheidsenquête door middel van Interview, België, 2004 (Health survey by means of interview, Belgium, 2004). Brussels: Wetenschappelijk Instituut Volksgezondheid; 2006.
12. Devroey D, Van Casteren V, Buntinx F. De epidemiologie van cerebrovasculaire incidenten in België (Epidemiology of cerebrovascular incidents in Belgium). Brussels: Wetenschappelijk Instituut Volksgezondheid; 2003.
13. National Institute for Statistics. Mathematische demografie. Bevolkingsvooruitzichten 2000-2050 per arrondissement (Mathematical demographics. Population estimates 2000-2050 per region). Brussels: National Institute for Statistics; 2001.
14. Vandenberghe H, Bastiaens H, Jockheer P, Orban T, Declercq E, Lafontaine MF, et al. Kwaliteitsbevordering in de huisartsgeneeskunde op basis van registratie van praktijkgegevens: diabetes type 2 en hypertensie (Quality enhancement in general practice on the basis of registration of practice data: type 2 diabetes and hypertension). Brussels: Wetenschappelijk Instituut Volksgezondheid; 2003.
15. P Autier J Creplet G Vansant C Brohet N Paquot E Muls 2003 The impact of reimbursement criteria on the appropriateness of 'statin' prescribing Eur J Cardiovasc Prev Rehabil 10 456 462
16. D Devroey W Betz 2003 An analysis of first authorizations for lipid-lowering drugs in Belgium Acta Clin Belg 58 152 158
17. D Devroey W Betz J Kartounian 2003 An evaluation of pharmaceutical treatment of dyslipidaemia among patients without diagnosed atherosclerotic disease in Belgium Int J Clin Pract 57 720 725
18. D Devroey J Kartounian J Vandevoorde W Betz M Cogge B De Man 2004 Primary prevention of coronary heart disease in general practice: a cross sectional population study Int J Clin Pract 58 130 138
19. Intermutualistisch Agentschap. De diabetesconventie (The diabetes convention). Brussels: Intermutualistisch Agentschap; 2005.
20. J Vlayen C Mathieu 2002 Treat-to-target: the challenge in diabetes care Aanwinsten in de inwendige geneeskunde 27 96 109
21. J Wens V Van Casteren E Vermeire P Van Royen L Pas J Denekens 2001 Diagnosis and treatment of type 2 diabetes in three Belgian regions. Registration via a network of sentinel general practices Eur J Epidemiol 17 743 750
22. DL Bhatt PG Steg EM Ohman AT Hirsch Y Ikeda JL Mas 2006 International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis JAMA 295 180 189
23. D Hayoz H Bounameaux CR Canova 2005 Swiss Atherothrombosis Survey: a field report on the occurrence of symptomatic and asymptomatic peripheral arterial disease J Intern Med 258 238 243
24. Organisation for Economic Co-operation and Development (OECD). Purchasing power parities. http://www.oecd.org/std/ppp. Accessed 5 Nov 2007.
25. Eurostat. Eurostat statistics. http://epp.eurostat.ec.europa.eu/portal. Accessed 9 Nov 2007.
26. RIZIV-INAMI. Tariffs and prices 2008. http://www.riziv.fgov.be. Accessed 16 Nov 2007.
27. Ministry of Social Affairs, Safety of Food and Environment. Financial feedback per pathology. https://tct.fgov.be/etct. Accessed 22 Nov 2007.
28. RIZIV-INAMI. Farmaceutische Kengetallen (Pharmaceutical numbers). http://www.riziv.fgov.be. Accessed 20 Nov 2007.
29. RIZIV-INAMI. Farmanet chronologische gegevens (Farmanet chronological data). http://www.riziv.fgov.be. Accessed 15 Oct 2007.
30. RIZIV-INAMI. Statistieken per groep van voorschrijvers (Statistics by type of prescriber). http://www.riziv.fgov.be. Accessed 16 Oct 2007.
31. RIZIV-INAMI. De top 25 van de werkzame bestanddelen in de uitgaven in de ambulante sector van de verzekering voor geneeskundige verzorging (Top 25 of active substances in expenditure in ambulatory care of the health Insurance system). http://www.riziv.fgov.be. Accessed 15 Nov 2007.
32. Collaborating WHO. Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical drug classification system. http://www.whocc.no. Accessed 15 Nov 2007.
33. Belgian Centre for Pharmacotherapeutic Information. http://www.bcfi.be. Accessed 15 Nov 2007.
34. RIZIV-INAMI. Jaarverslag 2006 (Annual accounts 2006). http://www.riziv.fgov.be. Accessed 20 Nov 2007.
35. Securex. Het absenteïsme in België 2004 (Absenteeism in Belgium 2004). Brussels: Securex; 2004.
36. RIZIV-INAMI. Gezondheidszorguitgaven in België in 2004 (Healthcare expenditure in Belgium in 2004). http://www.riziv.fgov.be. Accessed 23 Nov 2007.
37. J Leal R Luengo-Fernandez A Gray S Petersen M Rayner 2006 Economic burden of cardiovascular diseases in the enlarged European Union Eur Heart J 27 1610 1619
38. TL Kauf EJ Velazquez DR Crosslin WD Weaver R Diaz CB Granger 2006 The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry Am Heart J 151 206 212
39. The Cuore project. Epidemiology of cerebrovascular and cardiovascular diseases. http://www.cuore.iss.it. Accessed 30 Nov 2007.
40. M Bramkamp D Radovanovic P Erne TD Szucs 2007 Determinants of costs and the length of stay in acute coronary syndromes: a real life analysis of more than 10,000 patients Cardiovasc Drugs Ther 21 389 398
41. E Levy S Gabriel J Dinet 2003 The comparative medical costs of atherothrombotic disease in European countries Pharmacoeconomics 21 651 659
42. JF Spieler JL Lanoe P Amarenco 2004 Costs of stroke care according to handicap levels and stroke subtypes Cerebrovasc Dis 17 134 142
43. J Van Exel MA Koopmanschap JD Van Wijngaarden WJ Scholte Op Reimer 2003 Costs of stroke and stroke services: determinants of patient costs and a comparison of costs of regular care and care organised in stroke services Cost Eff Resour Alloc 1 2
44. PL Kolominsky-Rabas PU Heuschmann D Marschall M Emmert B Baltzer B Neundorfer 2006 Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project Stroke 37 1179 1183
45. HM Dewey AG Thrift C Mihalopoulos R Carter RA Macdonell JJ McNeil 2001 Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS) Stroke 32 2409 2416
46. AJ Schuit GC Wendel-Vos WM Verschuren ET Ronckers A Ament P Van Assema 2006 Effect of 5-year community intervention Hartslag Limburg on cardiovascular risk factors Am J Prev Med 30 237 242
47. ET Ronckers W Groot M Steenbakkers E Ruland A Ament 2006 Costs of the 'Hartslag Limburg' community heart health intervention BMC Public Health 6 51